Company intelligence / Profile preview

clock.bio

Cambridge, England, United Kingdomclock.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

clock.bio has developed a proprietary system to force human iPSCs to age in vitro, then uses genome-wide CRISPR screens to identify genes that drive self-rejuvenation. They have created an "Atlas of Rejuvenation Factors" with over 100 gene targets. The company recently raised $5.3M seed funding to validate these findings and prioritize therapeutic leads for future clinical translation. No clinical results reported yet.

Therapeutic areas: Other
Modalities: Gene therapy (future/targeted)Cell-based therapies (iPSC-derived)Functional genomics/CRISPR screens
Industry: Biotech

Partnerships

Not explicitly listed; seeking partners for future clinical trials and development.

Beyond the preview

Go deeper on clock.bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clock.bio.

Explore the full profile